Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells $38,388,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 1,400,000 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the transaction, the insider directly owned 13,736,547 shares of the company’s stock, valued at $376,656,118.74. This represents a 9.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Frank Torti also recently made the following trade(s):

• On Friday, February 20th, Frank Torti sold 1,012,610 shares of Roivant Sciences stock. The stock was sold at an average price of $27.15, for a total value of $27,492,361.50.
• On Monday, February 23rd, Frank Torti sold 587,390 shares of Roivant Sciences stock. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90.

Roivant Sciences Trading Up 1.4%

Shares of ROIV stock opened at $28.66 on Thursday. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $29.20. The company has a market capitalization of $20.51 billion, a P/E ratio of -24.50 and a beta of 1.22. The stock has a 50 day moving average of $23.66 and a two-hundred day moving average of $19.26.

Institutional Trading of Roivant Sciences

Several hedge funds have recently modified their holdings of the company. Jones Financial Companies Lllp boosted its holdings in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after acquiring an additional 1,148 shares in the last quarter. SBI Securities Co. Ltd. boosted its stake in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Finally, CWM LLC raised its holdings in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the topic of several analyst reports. The Goldman Sachs Group boosted their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Guggenheim raised their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $30.00 target price on shares of Roivant Sciences in a report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $28.69.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.